chr16-68738353-G-C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 1P and 1B. PM2_SupportingBS2_Supporting
This summary comes from the ClinGen Evidence Repository: The c.105G>C (NM_004360.5) variant in CDH1 is a missense variant predicted to predicted to cause substitution of Glu by Asp at amino acid 35 (p.Glu35Asp). This variant has been observed in more than 3 heterozygous individuals without GC, DGC, SRC tumours or LBC and whose families do not suggest HDGC (BS2_Supporting; Ambry, GeneDx, Invitae). This variant is absent from gnomAD 2.1.1 (PM2_Supporting). In summary, this variant meets the criteria to be classified as uncertain significance for DGLBCS based on the ACMG/AMP criteria applied, as specified by the ClinGen CDH1 VCEP (CDH1 VCEP specifications version 3.1): PM2_Supporting, BS2_Supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA16620230/MONDO:0100488/007
Frequency
Consequence
NM_004360.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDH1 | NM_004360.5 | c.105G>C | p.Glu35Asp | missense_variant | 2/16 | ENST00000261769.10 | NP_004351.1 | |
CDH1 | NM_001317184.2 | c.105G>C | p.Glu35Asp | missense_variant | 2/15 | NP_001304113.1 | ||
CDH1 | NM_001317185.2 | c.-1511G>C | 5_prime_UTR_variant | 2/16 | NP_001304114.1 | |||
CDH1 | NM_001317186.2 | c.-1715G>C | 5_prime_UTR_variant | 2/15 | NP_001304115.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CDH1 | ENST00000261769.10 | c.105G>C | p.Glu35Asp | missense_variant | 2/16 | 1 | NM_004360.5 | ENSP00000261769 | P1 | |
CDH1 | ENST00000422392.6 | c.105G>C | p.Glu35Asp | missense_variant | 2/15 | 1 | ENSP00000414946 | |||
CDH1 | ENST00000566612.5 | c.105G>C | p.Glu35Asp | missense_variant, NMD_transcript_variant | 2/15 | 1 | ENSP00000454782 | |||
CDH1 | ENST00000566510.5 | c.105G>C | p.Glu35Asp | missense_variant, NMD_transcript_variant | 2/15 | 5 | ENSP00000458139 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000143 AC: 2AN: 1398998Hom.: 0 Cov.: 31 AF XY: 0.00000145 AC XY: 1AN XY: 690008
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 10, 2016 | This variant is denoted CDH1 c.105G>C at the cDNA level, p.Glu35Asp (E35D) at the protein level, and results in the change of a Glutamic Acid to an Aspartic Acid (GAG>GAC). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. CDH1 Glu35Asp was not observed in approximately 5,400 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Glutamic Acid and Aspartic Acid share similar properties, this is considered a conservative amino acid substitution. CDH1 Glu35Asp occurs at a position that is not conserved and is located in the propeptide region (Brooks-Wilson 2004, Figueiredo 2013, UniProt). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether CDH1 Glu35Asp is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. - |
Hereditary diffuse gastric adenocarcinoma Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 12, 2023 | This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 35 of the CDH1 protein (p.Glu35Asp). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CDH1-related conditions. ClinVar contains an entry for this variant (Variation ID: 422466). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The aspartic acid amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
CDH1-related diffuse gastric and lobular breast cancer syndrome Uncertain:1
Uncertain significance, reviewed by expert panel | curation | ClinGen CDH1 Variant Curation Expert Panel | Aug 21, 2023 | The c.105G>C (NM_004360.5) variant in CDH1 is a missense variant predicted to predicted to cause substitution of Glu by Asp at amino acid 35 (p.Glu35Asp). This variant has been observed in more than 3 heterozygous individuals without GC, DGC, SRC tumours or LBC and whose families do not suggest HDGC (BS2_Supporting; Ambry, GeneDx, Invitae). This variant is absent from gnomAD 2.1.1 (PM2_Supporting). In summary, this variant meets the criteria to be classified as uncertain significance for DGLBCS based on the ACMG/AMP criteria applied, as specified by the ClinGen CDH1 VCEP (CDH1 VCEP specifications version 3.1): PM2_Supporting, BS2_Supporting. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 06, 2019 | The p.E35D variant (also known as c.105G>C), located in coding exon 2 of the CDH1 gene, results from a G to C substitution at nucleotide position 105. The glutamic acid at codon 35 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at